Ruthenium complexes can target determinants of tumour malignancy.
about
The elements of life and medicinesRuthenium anticancer compounds: myths and realities of the emerging metal-based drugs.Bifunctional polypyridyl-Ru(II) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy.DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells.Preparation of organometallic ruthenium-arene-diaminotriazine complexes as binding agents to DNA.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSNew ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.New trends for metal complexes with anticancer activityMechanism of cellular uptake of a ruthenium polypyridyl complex.Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Enhancing vascular relaxing effects of nitric oxide-donor ruthenium complexes.Ruthenium complexes as antimicrobial agents.Palladium(II) Complexes of Biorelevant Ligands. Synthesis, Structures, Cytotoxicity and Rich DNA/HSA Interaction Studies.Anti-tumor activity and mechanism of apoptosis of A549 induced by ruthenium complex.Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.Anticancer Organometallic Osmium(II)-p-cymene Complexes.Synthesis and Structural Evaluation of Organo-Ruthenium Complexes with β-Diketonates.Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity.NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.Phenanthroline ligands are biologically more active than their corresponding ruthenium(II) arene complexes.The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers.Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.Factors that influence the antiproliferative activity of half sandwich Ru(II)-[9]aneS3 coordination compounds: activation kinetics and interaction with guanine derivatives.Mechanism of cytotoxicity and cellular uptake of lipophilic inert dinuclear polypyridylruthenium(II) complexes.Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cellsAlbumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).Cytotoxic (salen)ruthenium(iii) anticancer complexes exhibit different modes of cell death directed by axial ligands.Characterization of metalloanticancer capacity of an agglutinin from wheat.A general strategy to add diversity to ruthenium arene complexes with bioactive organic compounds via a coordinated (4-hydroxyphenyl)diphenylphosphine ligand.The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
P2860
Q28649323-D54DA1D8-4C7F-446B-A78F-55721980D735Q30403317-14ED76A0-D9BB-491B-9125-8AD4C81F4BD9Q30655635-EF56A14B-35AA-472C-BB41-23BC4D49769FQ31043552-2E78A3B7-1798-42C3-ACCA-C1530D327491Q33848447-5FC87A78-F522-4BD9-A4A8-470E097ED979Q34151556-3E121811-C5C7-4CEF-B90A-C7317699FC18Q34394993-8C14789F-6CD7-421D-A377-A94FE6257D0AQ35029887-6CC81758-8886-4B23-9A8E-C4436CFA1D64Q37044080-F8619BE6-52FF-458E-A926-32C01417094CQ37354918-F963F5A5-35A1-46A4-9266-C7B8F7CC54F7Q37603642-A5A9D496-DC81-4A20-B1C5-CA2C2EF400A8Q38096196-8AC25321-465A-490B-82AC-D8AB20518654Q38221279-73D5F14E-3EC7-47E5-BD60-E153E5B082D2Q38365877-09B69FF4-5313-4E7C-885B-BD03D0FB9550Q38693914-5D471AC7-182E-4C7A-A720-1A95B7687869Q38746692-8980B619-7F0A-47D5-9B3D-57E271EF2D9DQ38809475-FD8B33DB-629A-4150-B747-1A936F082E3CQ38835381-68591533-013C-49D6-B173-351E0A26993BQ38838114-741A84B3-8205-4AF6-BD1E-E6295A254AA8Q38851401-94F287BE-8A1E-469C-8A9F-B0625C8B9CAFQ38946217-2C8B48D3-CCCC-4533-BF14-1ED9C8878D7EQ38962540-CDBED8B1-9FA1-42BA-870B-5BE4EF2CCFA7Q38979908-90932A53-331E-472A-87DF-9FA266E0912DQ39044622-CE912170-D16E-4BAD-8B4A-802491781DFFQ39246566-877E7E51-A8C9-4C69-8588-6CF122D0C6F5Q39294174-B3072F67-15F7-453B-8768-CAB56004D58CQ39295123-7EA1C041-7E40-4998-A1A9-4212078F8EABQ39562465-0A3D368F-30E0-4E9E-A631-E214E4C95322Q39744502-D1765082-A87C-491E-94FC-815D23A8B6D2Q39900189-AB68E6A4-ADE0-4E41-AAF1-B9B260D912B5Q40737623-768AFF58-9A62-41E9-AB1A-933B6AB44263Q40786041-7F3E75EA-30B1-4431-9709-442CEA71B4F5Q42040747-568649D5-389F-4B4D-8EB0-3C2EB6F0A08FQ42576712-7AC8B982-4B17-49CD-BB43-89361EA71E74Q43242098-108D3AAE-FB6B-4521-85AA-8D99772423AEQ47135597-4565269B-2A8A-40C3-B80E-8712EEEABAEDQ47313332-59A05207-A5A8-4E5A-A48D-7467F368B16BQ48259223-DECB12F7-3BF7-4DF6-93B5-37B8A908B611Q49611544-C8CC563F-5802-4E63-97B7-E3C0DB793C1AQ50063144-E6CF4531-8C50-4DDC-BBD1-1C36DF5FC169
P2860
Ruthenium complexes can target determinants of tumour malignancy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Ruthenium complexes can target determinants of tumour malignancy.
@ast
Ruthenium complexes can target determinants of tumour malignancy.
@en
type
label
Ruthenium complexes can target determinants of tumour malignancy.
@ast
Ruthenium complexes can target determinants of tumour malignancy.
@en
prefLabel
Ruthenium complexes can target determinants of tumour malignancy.
@ast
Ruthenium complexes can target determinants of tumour malignancy.
@en
P356
P1433
P1476
Ruthenium complexes can target determinants of tumour malignancy.
@en
P2093
P304
P356
10.1039/B617769G
P407
P577
2007-02-28T00:00:00Z